BMT CTN 2203
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 572 patients (estimated)
- Sponsors
- Incyte Corporation
- Collaborators
- Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, JAK1 Inhibitor, JAK2 Inhibitor, Tyrosine Kinase (TK) Inhibitor, Post-Allogeneic Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 2152
- NCT Identifier
- NCT06615050
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.